P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 20.93 CNY -0.05% Market Closed
Market Cap: 15.3B CNY
Have any thoughts about
Pacific Shuanglin Bio pharmacy Co Ltd?
Write Note

Net Margin
Pacific Shuanglin Bio pharmacy Co Ltd

29.1%
Current
24%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
29.1%
=
Net Income
828.6m
/
Revenue
2.8B

Net Margin Across Competitors

Country CN
Market Cap 15.3B CNY
Net Margin
29%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.2B USD
Net Margin
9%
Country US
Market Cap 142B USD
Net Margin
13%
Country US
Market Cap 115B USD
Net Margin
0%
Country US
Market Cap 101.6B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78.5B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
15.3B CNY
Industry
Biotechnology

In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.

Intrinsic Value
33.41 CNY
Undervaluation 37%
Intrinsic Value
Price
P

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
29.1%
=
Net Income
828.6m
/
Revenue
2.8B
What is the Net Margin of Pacific Shuanglin Bio pharmacy Co Ltd?

Based on Pacific Shuanglin Bio pharmacy Co Ltd's most recent financial statements, the company has Net Margin of 29.1%.